Alto Neuroscience CFO sells 134,886 shares
The reported option exercises and sales occurred under a Rule 10b5-1 plan adopted June 30, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Alto Neuroscience, Inc. (ANRO) President and CFO Nicholas Conrad Smith exercised options to acquire 134,886 common shares at $2.35 per share on September 29 and 30, 2026, and sold 134,886 shares across those dates. On September 29, he sold 110,830 shares at a weighted average $26.5826 per share. On September 30, he sold 23,170 shares at $25.7786 and 886 shares at $26.87. The transactions were made under a Rule 10b5-1 trading plan adopted June 30, 2026.
Insider Trade Summary
Exercise and Sale: 134,886 shares ($3.25M approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
Smith Nicholas Conrad
Role
PRESIDENT AND CFO
Sold
134,886 shs ($3.57M)
Approx. gross sale proceeds
$3.57M
Approx. exercise cost
$317K
Approx. pre-tax spread
$3.25M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Buy) F1, F3 | 24,056 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 24,056 | $2.35 | $57K |
| Sale | Common Stock F1 | 23,170 | $25.7786 | $597K |
| Sale | Common Stock F1 | 886 | $26.87 | $24K |
| Exercise | Employee Stock Option (Right to Buy) F1, F3 | 56,455 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (Right to Buy) F1, F4 | 54,375 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 56,455 | $2.35 | $133K |
| Exercise | Common Stock F1 | 54,375 | $2.35 | $128K |
| Sale | Common Stock F1, F2 | 110,830 | $26.5826 | $2.95M |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 157,443 contracts (Direct);
Common Stock — 24,060 shares (Direct)
Footnotes (4)
- F1. This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.
- F2. This price is a weighted average price. These securities were sold in multiple transactions at prices ranging from $26.5513 to $26.5902 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F3. One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date.
- F4. 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Key Figures
Common shares acquired through option exercises: 134,886 shares
Option exercise price: $2.35 per share
Common shares sold: 134,886 shares
+4 more
7 metrics
Common shares acquired through option exercises
134,886 shares
September 29 and 30, 2026
Option exercise price
$2.35 per share
Reported option exercises
Common shares sold
134,886 shares
September 29 and 30, 2026
September 29 sale
110,830 shares at a weighted average $26.5826 per share
September 29, 2026
September 29 sale price range
$26.5513 to $26.5902 per share
Inclusive range across multiple transactions
September 30 sale
23,170 shares at $25.7786 per share
September 30, 2026
September 30 sale
886 shares at $26.87 per share
September 30, 2026
Key Terms
Rule 10b5-1 trading plan, weighted average price, vested
3 terms
Rule 10b5-1 trading plan regulatory
"pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"This price is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
vested financial
"25% of the shares underlying the option vested"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Were Nicholas Conrad Smith's ANRO transactions under a 10b5-1 plan?
Yes. The transactions were made under a Rule 10b5-1 trading plan adopted June 30, 2026.
What was the price range for Nicholas Conrad Smith's September 29 ANRO sales?
The shares were sold in multiple transactions at prices ranging from $26.5513 to $26.5902 per share, inclusive. The reported weighted average price was $26.5826 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
